RU2407527C2 - Способы, композиции и изделия, способствующие лечению рака - Google Patents

Способы, композиции и изделия, способствующие лечению рака Download PDF

Info

Publication number
RU2407527C2
RU2407527C2 RU2009107085/14A RU2009107085A RU2407527C2 RU 2407527 C2 RU2407527 C2 RU 2407527C2 RU 2009107085/14 A RU2009107085/14 A RU 2009107085/14A RU 2009107085 A RU2009107085 A RU 2009107085A RU 2407527 C2 RU2407527 C2 RU 2407527C2
Authority
RU
Russia
Prior art keywords
tumor
irl1620
rats
paclitaxel
saline
Prior art date
Application number
RU2009107085/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2009107085A (ru
Inventor
Анил ГУЛАТИ (US)
Анил ГУЛАТИ
Гуру РЕДДИ (US)
Гуру РЕДДИ
Луиджи ЛЕНАЗ (US)
Луиджи ЛЕНАЗ
Original Assignee
Спектрум Фармасьютикалз, Инк.
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Спектрум Фармасьютикалз, Инк., Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс filed Critical Спектрум Фармасьютикалз, Инк.
Publication of RU2009107085A publication Critical patent/RU2009107085A/ru
Application granted granted Critical
Publication of RU2407527C2 publication Critical patent/RU2407527C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2009107085/14A 2006-08-02 2007-07-20 Способы, композиции и изделия, способствующие лечению рака RU2407527C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/461,961 US20070032422A1 (en) 2002-10-24 2006-08-02 Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US11/461,961 2006-08-02

Publications (2)

Publication Number Publication Date
RU2009107085A RU2009107085A (ru) 2010-09-10
RU2407527C2 true RU2407527C2 (ru) 2010-12-27

Family

ID=38752363

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009107085/14A RU2407527C2 (ru) 2006-08-02 2007-07-20 Способы, композиции и изделия, способствующие лечению рака

Country Status (17)

Country Link
US (4) US20070032422A1 (cg-RX-API-DMAC10.html)
EP (2) EP2450037A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009545609A (cg-RX-API-DMAC10.html)
KR (1) KR101507178B1 (cg-RX-API-DMAC10.html)
CN (1) CN101522186B (cg-RX-API-DMAC10.html)
AR (1) AR062177A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0715521A2 (cg-RX-API-DMAC10.html)
CA (1) CA2658340C (cg-RX-API-DMAC10.html)
DK (1) DK2046323T3 (cg-RX-API-DMAC10.html)
ES (1) ES2402232T3 (cg-RX-API-DMAC10.html)
IL (1) IL196825A (cg-RX-API-DMAC10.html)
MX (1) MX2009001233A (cg-RX-API-DMAC10.html)
NO (1) NO20090915L (cg-RX-API-DMAC10.html)
RU (1) RU2407527C2 (cg-RX-API-DMAC10.html)
TW (1) TWI469776B (cg-RX-API-DMAC10.html)
WO (1) WO2008016793A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200900017B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
ES2541657T3 (es) 2006-08-31 2015-07-23 Spectrum Pharmaceuticals, Inc. Sensibilización de células tumorales a terapia de radiación a través de la administración de agonistas de endotelina
PL2182977T3 (pl) * 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
CA3023227C (en) * 2016-05-06 2021-11-02 Biodynamic Research Foundation Pharmaceutical composition containing macromolecular drug
WO2024222663A1 (zh) * 2023-04-26 2024-10-31 拜西欧斯（北京）生物技术有限公司 多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
EP0950418A2 (en) 1998-04-14 1999-10-20 Takeda Chemical Industries, Ltd. Composition for preventing or treating ischemic disease
PT1115391E (pt) 1998-09-25 2003-02-28 Warner Lambert Co Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
CN1729012B (zh) * 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
US8217010B2 (en) * 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
WO2006057988A2 (en) 2004-11-22 2006-06-01 The Board Of Trustees Of The University Of Illinois Use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging
CA2598439A1 (en) * 2005-02-22 2006-08-31 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
ES2541657T3 (es) 2006-08-31 2015-07-23 Spectrum Pharmaceuticals, Inc. Sensibilización de células tumorales a terapia de radiación a través de la administración de agonistas de endotelina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAJESHKUMAR N V et al: Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats, BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, vol. 94, №3, 2005 p.237-247. *

Also Published As

Publication number Publication date
ZA200900017B (en) 2009-11-25
RU2009107085A (ru) 2010-09-10
HK1129601A1 (en) 2009-12-04
IL196825A0 (en) 2011-08-01
MX2009001233A (es) 2009-02-12
EP2046323B1 (en) 2013-02-13
US20130102543A1 (en) 2013-04-25
US20090155206A1 (en) 2009-06-18
EP2450037A1 (en) 2012-05-09
TW200820965A (en) 2008-05-16
NO20090915L (no) 2009-02-27
EP2046323A2 (en) 2009-04-15
CN101522186A (zh) 2009-09-02
US8030278B2 (en) 2011-10-04
IL196825A (en) 2015-08-31
DK2046323T3 (da) 2013-04-22
AR062177A1 (es) 2008-10-22
US20110315575A1 (en) 2011-12-29
US20070032422A1 (en) 2007-02-08
WO2008016793A2 (en) 2008-02-07
US8440620B2 (en) 2013-05-14
US8729023B2 (en) 2014-05-20
CN101522186B (zh) 2013-06-05
CA2658340A1 (en) 2008-02-07
KR20090034355A (ko) 2009-04-07
KR101507178B1 (ko) 2015-03-30
BRPI0715521A2 (pt) 2013-06-25
JP2009545609A (ja) 2009-12-24
ES2402232T3 (es) 2013-04-30
TWI469776B (zh) 2015-01-21
CA2658340C (en) 2015-11-24
WO2008016793A3 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
US8703709B2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US8729023B2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers
JP2012214519A (ja) 固形腫瘍の治療に貢献するための方法、組成物及び製品
KR101547361B1 (ko) 엔도셀린 효능제 투여를 통한 방사선 요법에 대한 종양 세포의 감작
US8642026B2 (en) Methods and compositions for contributing to the treatment of cancers
EP2144607B1 (en) Compositions for contributing to the treatment of cancers
HK1129601B (en) Compositions for contributing to the treatment of cancers
HK1140145B (en) Compositions for contributing to the treatment of cancers

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160721